Thomas Trolle

Technical University of Denmark CWIS ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 4

Top Topics

Endoplasmic Reticulum

Electronic Health Record

Top Venues

Future oncology (London, England)

Journal of immunology (Baltimore, Md. : 1950)

This page only lists publications with an associated author ORCID identifier.

Publications

Nadia Viborg, Michail Angelos Pavlidis, Marina Barrio Calvo, Stine Friis, Thomas Trolle, Anders Bundgaard Sørensen, Christian Bahne Thygesen, Søren Vester Kofoed, Daniela Kleine-Kohlbrecher, Sine Reker Hadrup, Birgitte Rønø
DNA based neoepitope vaccination induces tumor control in syngeneic mouse models. NPJ vaccines 8 (1) (2023)
Georgina V Long, Pier Francesco Ferrucci, Adnan Khattak, Tarek M Meniawy, Patrick Alexander Ott, Michael Chisamore, Thomas Trolle, Agon Hyseni, Erik Heegaard
KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma. Future oncology (London, England) (2022)
Thomas Trolle, Curtis P McMurtrey, John Sidney, Wilfried Bardet, Sean C Osborn, Thomas Kaever, Alessandro Sette, William H Hildebrand, Morten Nielsen, Bjoern Peters
The Length Distribution of Class I-Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele-Specific Binding Preference. Journal of immunology (Baltimore, Md. : 1950) 196 (4) (2016)
Curtis McMurtrey, Thomas Trolle, Tiffany Sansom, Soumya G Remesh, Thomas Kaever, Wilfried Bardet, Kenneth Jackson, Rima McLeod, Alessandro Sette, Morten Nielsen, Dirk M Zajonc, Ira J Blader, Bjoern Peters, William Hildebrand
Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove. eLife 5 (2016)